Paroxysmal Nocturnal Hemoglobinuria: A Case Report in a Pandemic Environment

Area of Science:

• Hematology
• Immunology
• Vascular Medicine

Background:

• Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal, complement-mediated hemolytic anemia.
• PNH is often associated with marrow failure and a high risk of thrombophilia.

Observation:

• A 41-year-old male with classic PNH, not previously treated with complement inhibitors, developed splenic vein thrombosis.
• This major adverse event occurred after receiving a vaccination protocol for meningococcal disease.

Findings:

• Eculizumab treatment was effective in managing intravascular hemolysis and preventing further thrombotic events.
• Anticoagulant therapy was also administered as part of the treatment regimen.

Implications:

• Vaccination protocols in PNH patients necessitate careful monitoring to prevent severe outcomes such as vaccine-induced thrombosis.
• Eculizumab shows potential in mitigating complement-mediated inflammation, possibly protecting against breakthrough hemolysis during infections like SARS-CoV-2.
• While intravascular hemolysis is controlled, research into new therapies for residual extravascular hemolysis offers a positive outlook for PNH patients.